Used in research to modulate pain signaling by targeting the interaction between CRMP2 and Ubc9, which influences the trafficking of the NaV1.7 sodium channel. This inhibition reduces sodium current in sensory neurons, making it a tool compound for studying chronic pain pathways. It shows potential in developing non-opioid analgesics, particularly for neuropathic and inflammatory pain conditions. Its selectivity helps minimize off-target effects in neuronal excitability studies.